Tivic Health Systems ( (TIVC) ) has issued an announcement.
On February 11, 2025, Tivic Health Systems entered into an exclusive licensing agreement with Statera Biopharma to acquire rights to the TLR5 agonist program, including Entolimod for treating Acute Radiation Syndrome (ARS), and options for additional indications. This agreement positions Tivic as a diversified therapeutics company with a broadened clinical pipeline, potentially leading to FDA approval for ARS treatment within 24 months. Tivic’s acquisition aligns with its strategic transformation towards tackling immune and autonomic dysregulation. The deal involves milestone and royalty payments and allows Tivic to expand its product offerings, potentially benefiting shareholders by managing investments strategically.
More about Tivic Health Systems
Tivic Health is a diversified therapeutics company that focuses on leveraging the immune and autonomic nervous systems to combat diseases. The company’s approach combines bioelectronic and biologic medicines to address conditions related to immune dysregulation and dysautonomia, targeting disorders through both neural pathways and molecular methods. Tivic Health’s first FDA-approved product, ClearUP, is a treatment for sinus pain and pressure and is available through online retailers and commercial distributors.
YTD Price Performance: -30.88%
Average Trading Volume: 2,242,389
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.2M
For a thorough assessment of TIVC stock, go to TipRanks’ Stock Analysis page.